Market Analysis - Cell Tissue Science 2019
The tissue engineering and organ regeneration market is a very important part of the sector of medicine. Tissue engineering and organ regeneration are primarily used for treating burns and accident wounds, for cosmetic surgeries, in correcting birth defects, wound care, orthopedics, and in neurology, amongst others. The recent development within the engineering cell growth section has inspired the attention of healthcare field to adopt it thanks to the increased knowledge bank concerning the procedure and also the principle behind it.
The global regenerative medicines market is anticipated to achieve USD 50.11 billion by 2021, registering a CAGR of 12.7% during the period of 2015-2021. On the back of expanding demand for bone & joint reconstructive surgeries within the nation, North America with the most shares in global regenerative dominated the market followed by Europe in 2015. Further, it's projected that by 2019 Europe might surpass the North America market in the field of stem cell and regenerative medicine. Eastern and Western Europe are anticipated to demonstrate extended request in light of the fact that the requirement for transplants through regenerative drugs will be expanding for several applications in coming future. Asia-Pacific countries are required to show up-surged request amid 2015-2021. In addition to that, Asia-Pacific transforming into one of the prime mainlands in providing regenerative medicines on bone and joint in nations like India, China, Japan and South Korea are anticipated to give a lift to the stem cell market within these countries.
Tissue engineering accounted for the highest share in industrial development once they participate nationwide or geographically within the field of producing regenerative medicines. When we look into the geographic distribution of tissue engineering companies and research institutes, the U.S.A with 52 leads the market followed by Germany (21%), Japan (16%), the United Kingdom (7%), and Sweden (4%).
Today’s Market Study of Tissue Engineering and Regenerative Medicine in USA, Europe, Middle East and Asia Pacific
USA: The global regenerative medicine market size is predicted to reach USD 49.41 billion by the year 2021.North America contributed the biggest share in the worldwide regenerative medicines market and was overwhelmed by the U.S.A.
Europe: The worldwide tissue engineering and regeneration market came to $17 billion in 2013. This market is anticipated to grow to almost $20.8 billion in 2014 and $56.9 billion in 2019.
Middle East: The Middle East and Africa regenerative medicines market is expected to achieve USD 5.75 billion by 2021 from USD 2.03 billion in 2016, developing at a CAGR of 23.15% amid the estimate time frame 2016-2021. Regenerative medicines repair, replace or regenerate human cells, tissues, or organs affected due to injury, aging processes, congenital defects, and damage due to trauma.
Asia-Pacific: Asia-Pacific regenerative medicines market is relied upon to achieve UUSD 10.71 billion by 2021 from USD 3.01 billion in 2016, developing at a CAGR of 28.90% during the time period 2016-2021. Cell-based products sector is estimated to account for larger share of Asia-Pacific regenerative medicines market by product in 2016.
Tissue Science is expected to be the fastest emerging technology because of the tremendous potential of gene therapy in minimizing immune rejections, which commonly occur after transplantations. Asia-Pacific would be the fastest growing region for regenerative medicine market. Europe and North America together accounted for over 3/4th of the market revenue and anticipated to be a most profitable regional market.
Tissue Science Society worldwide:
Cell and Gene Therapy Societies Worldwide:
Industries and Institute working the field of Stem Cells in Singapore: